

Date: 8 March 2022

## **Urgent Field Safety Notice**

Thermo Scientific™ ProSpecT™ STEC (Shiga Toxin E. coli) Microplate Assay (R2474096)

For Attention of\*: Lab Managers

Contact details of local representative (name, e-mail, telephone, address etc.)\*

E.mail: mbd.vigilance@thermofisher.com Telephone: +44(0) 1256 841144

Fax: +44(0) 1256 479525



## **Urgent Field Safety Notice (FSN)**

## Thermo Scientific ProSpecT STEC (Shiga Toxin E. coli) Microplate Assay

	1. Information on Affected Devices*
1.	1. Device Type(s)*
	IVD
1.	2. Commercial name(s)
	Thermo Scientific ProSpecT STEC (Shiga Toxin E. coli) Microplate Assay
1.	Unique Device Identifier(s) (UDI-DI)
	05056080501673
1.	4. Primary clinical purpose of device(s)*
	The Thermo Scientific ProSpecT STEC (Shiga Toxin E. coli) Microplate Assay
	is intended for the qualitative detection of Shiga Toxin (Stx1 and Stx2) in
	aqueous extracts of faecal specimens and broth enriched faecal cultures. The
	test is intended for use as an aid in the diagnosis of enterohemorrhagic E. coli
	infections.
1.	5. Device Model/Catalogue/part number(s)*
	R2474096
1.	6. Software version
	N/A
1.	7. Affected serial or lot number range
	3282613
	3301257
1.	8. Associated devices
	N/A

	2. Reason for Field Safety Corrective Action (FSCA)*				
2.	Description of the product problem*				
		An internal technical investigation has determined that R2474096 ProSpecT Shiga Toxin E.coli (STEC) Microplate Assay Lots. 3282613 and 3301257 are failing to meet IFU criteria with multiple wells failing for the positive control (PCK) which would invalidate the test, however, where borderline results are obtained a loss in sensitivity of the conjugate may lead to false negative results.			
2.	2.	Hazard giving rise to the FSCA*			
		Delay to patient treatment			
2.	3.	Probability of problem arising			
		High			
2.	4.	Predicted risk to patient/users			
		There should be no immediate or long-term health consequences from use of R2474096 ProSpecT Shiga Toxin E.coli (STEC) Microplate Assay Lots. 3282613 and 3301257. The clinical risk should therefore be considered as negligible.			
2.	5.	Further information to help characterise the problem			
		N/A			



2.	Background on Issue				
	One complaint (ref: 9000052657) has been received. A customer stated that the positive control is 'too low' for the Lot. 3301257.				
2.	2. 7. Other information relevant to FSCA				
	Lot	DOM (YYYY-MM-DD)	Exp. Date (YYYY-MM-DD)		
	3282613	2021-06-22	2202-05-31		
	3301257	2021-08-31	2022-05-31		

		3. Type o	f Action to mitigate the	Dick*		
3.	or type or to more the same transfer					
5.		1. Action to be taken by the oser				
		☐ Identify Device ☐ Quarantine Device ☐ Return Device ☒ Destroy Device				
		☐ On-site device modification/inspection				
		☐ Follow patient management re	ecommendations			
		☐ Take note of amendment/reinforcement of Instructions For Use (IFU)				
		☐ Other ☐ None				
3.	2.	By when should the action be completed?	Immediately			
3.	3.	Particular considerations for:	IVD			
	Is follow-up of patients or review of patients' previous results recommended?					
		We request that the requirement determined by the appropriate	•	st results should be		
3.		Is customer Reply Required? * Yes				
		yes, form attached specifying of				
3.	5.	. Action Being Taken by the Manufacturer				
			On-site device modification/insp	ection		
		☐ Software upgrade ☐ IF	FU or labelling change			
		□ Other □ N	Vone			
3	6.	By when should the action be completed?	As soon as possible			
3.	7.	Is the FSN required to be communicated to the patient No /lay user?				
3	8. If yes, has manufacturer provided additional information suitable for the patient/lay user in a patient/lay or non-professional user information letter/sh Choose an item.  Choose an item.					



The world leader in serving science

Rev 1: September 2018 FSN Ref: FSN-2022-003

	4. Genera	al Information*	
4.	1. FSN Type*	New	
4.	For updated FSN, reference number and date of previous FSN	N/A	
4.	3. For Updated FSN, key new information as follows:		
	N/A		
4.	4. Further advice or information already expected in follow-up FSN? *	Not planned yet	
	5. If follow-up FSN expected, what is	s the further advice expected to relate to:	
4	N/A		
4	Anticipated timescale for follow- up FSN	N/A	
4.	7. Manufacturer information (For contact details of local representative refer to page 1 of this FSN)		
	a. Company Name	Thermo Fisher Scientific	
	b. Address	Remel Europe Ltd, Clipper Boulevard West Dartford Kent	
	c. Website address	DA26PT www.thermofisher.com	
4.		ority of your country has been informed about	
4.	9. List of attachments/appendices:		
4.	10. Name		
	Signature		

Transmission of this Field Safety Notice
This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate).
Please transfer this notice to other organisations on which this action has an impact. (As appropriate).
Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.
Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback.*



## **Customer Reply Form**

1. Field Safety Notice (FSN) information						
FSN Reference number* 2022-003						
		8 March 2022				
Product/ Device name*		Thermo Sci	Thermo Scientific ProSpecT STEC (Shiga Toxin E. coli)			
		Microplate A	Assay	,		
Product Code(s	5)	R2474096				
Batch/Serial Nu	mber (s)	3282613 & 3	30125	57		
2. Customer	Details					
Account Number	er					
Organisation Na	ame*					
Organisation Ad	ddress*					
Department/Un	it					
Shipping addres	ss if different to above					
Contact Name*						
Title or Function	า					
Telephone num	ber*					
Email*						
3. Customer	action undertaken on b	ehalf of Healt	hcare	Organisation		
☐ I confirm	receipt of the Field Safe	ty Notice and		-		
that I rea	d and understood its cor	ntent.				
I perform	ed all actions requested	by the FSN.				
The infor	mation and required acti	ons have				
│	ught to the attention of a	ll relevant				
users and	d executed.					
☐ I have re	turned affected devices -	- enter	Qty:	Lot/Serial Number:	Date Returned	
│	of devices returned and o	date		(DD/MM/YY)		
complete	complete or N/A		Comr	ments:		
	I have destroyed affected devices – enter number destroyed and date complete.		Qty:	Lot/Serial Number:	Date Returned	
│			0.		(DD/MM/YY)	
			Qty	•	•	
			Com	ments:		
	No affected devices are available for return/ destruction					
☐ Other Ac	Other Action (Define):					
I do not h	I do not have any affected devices.					
	I have a query please contact me (e.g. need					
for replacement of the product).						
Print Name*						
Signature*						
Date*						
4. Return acknowledgement to sender						
Email			MBD.vigilance@thermofisher.com			
Telephone Number & Fax		Tel: +44(0) 1256 841144				
			rax:	+44(0) 1256 479525		
Postal Address  Deadline for returning the reply form*  05 April 2				pril 2022		
ı Deaume idi iel	arring the reply follo		· UJ A	DIII EULL		

Mandatory fields are marked with \*



It is important that your organisation takes the actions detailed in the FSN and confirms that you have received the FSN.

Your organisation's reply is the evidence we need to monitor the progress of the corrective actions.